Based on the CAPRICOR THERAP. DL-001 stock forecast from 0 analysts, the average analyst target price for CAPRICOR THERAP. DL-001 is not available over the next 12 months. CAPRICOR THERAP. DL-001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of CAPRICOR THERAP. DL-001 is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, CAPRICOR THERAP. DL-001’s stock price was EUR 12.20. CAPRICOR THERAP. DL-001’s stock price has changed by -7.72% over the past week, -28.15% over the past month and +224.47% over the last year.
No recent analyst target price found for CAPRICOR THERAP. DL-001
No recent average analyst rating found for CAPRICOR THERAP. DL-001
Company Overview CAPRICOR THERAP. DL-001
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California. Read Less
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, ...Read More
Frequently Asked Questions About CAPRICOR THERAP. DL-001 (4LN2:F) Stock
Stock Target Advisor's fundamental analysis for CAPRICOR THERAP. DL-001's stock is Bearish.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate if its overvalued.
The last closing price of 4LN2:F's stock was EUR 12.20.
The most recent market capitalization for 4LN2:F is EUR 0.65B.
Unfortunately we do not have enough analyst data on 4LN2:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CAPRICOR THERAP. DL-001's stock.
As per our most recent records CAPRICOR THERAP. DL-001 has 101 Employees.
CAPRICOR THERAP. DL-001's registered address is 10865 Road to the Cure, San Diego, CA, United States, 92121.
You can get more information about it from CAPRICOR THERAP. DL-001's website at https://www.capricor.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About CAPRICOR THERAP. DL-001 (4LN2:F) Stock
Stock Target Advisor's fundamental analysis for CAPRICOR THERAP. DL-001's stock is Bearish.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4LN2:F's stock to indicate if its overvalued.
The last closing price of 4LN2:F's stock was EUR 12.20.
The most recent market capitalization for 4LN2:F is EUR 0.65B.
Unfortunately we do not have enough analyst data on 4LN2:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CAPRICOR THERAP. DL-001's stock.
As per our most recent records CAPRICOR THERAP. DL-001 has 101 Employees.
CAPRICOR THERAP. DL-001's registered address is 10865 Road to the Cure, San Diego, CA, United States, 92121.
You can get more information about it from CAPRICOR THERAP. DL-001's website at https://www.capricor.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4LN2:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
